Lilly discontinues potential osteoporosis drug arzoxifene
This article was originally published in Scrip
Lilly has discontinued development of its selective oestrogen receptor modulator (SERM) arzoxifene after preliminary results show that it failed to meet the secondary endpoints of the GJAD "GENERATIONS" Phase III study in osteoporosis, as well as being associated with serious adverse events.
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.